Literature DB >> 7541528

Longitudinal evaluation of serum androgen levels in men with and without prostate cancer.

H B Carter1, J D Pearson, E J Metter, D W Chan, R Andres, J L Fozard, W Rosner, P C Walsh.   

Abstract

Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age-matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6-9 over a period from 7-25 years prior to the diagnosis of prostate disease. There were no significant differences in age-adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0-5, 5-10, and 10-15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541528     DOI: 10.1002/pros.2990270106

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  16 in total

Review 1.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

Review 2.  Risks versus benefits of testosterone therapy in elderly men.

Authors:  S Basaria; A S Dobs
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

3.  Case scenarios in androgen deficiency.

Authors:  Andrew McCullough
Journal:  Rev Urol       Date:  2003

4.  Novel biomarkers for risk of prostate cancer: results from a case-control study.

Authors:  Li Yang; Nilesh W Gaikwad; Jane Meza; Ercole L Cavalieri; Paola Muti; Bruce Trock; Eleanor G Rogan
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

5.  The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.

Authors:  Farid Saad; Louis J Gooren
Journal:  J Obes       Date:  2010-08-10

6.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

7.  Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.

Authors:  Phillip M Pierorazio; Luigi Ferrucci; Anna Kettermann; Dan L Longo; E Jeffrey Metter; H Ballentine Carter
Journal:  BJU Int       Date:  2009-09-14       Impact factor: 5.588

8.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Alan R Kristal; Jeannette M Schenk; YoonJu Song; Kathryn B Arnold; Marian L Neuhouser; Phyllis J Goodman; Daniel W Lin; Frank Z Stanczyk; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2008-10-21       Impact factor: 4.897

9.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

10.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

Authors:  Andrew W Roddam; Naomi E Allen; Paul Appleby; Timothy J Key
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.